View profile

FarmaKology Newsletter - Issue #21

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
FarmaKology Newsletter - Issue #21
By Abdul Menum Ali • Issue #21 • View online
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “abdul@farmakology.com”, and happy to have you featured on our newsletter (+1000 Subscribers ) !

Today's Startup
HeartFlow
HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease–the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide.
News
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists).
China will strengthen monitoring of the supply and prices of drugs in shortage, according to a guideline issued by the General Office of the State Council.The guideline said a supply monitoring mechanism will be established to enhance coordination between multiple information platforms, noting the information concerning the registration, production, procurement and prices of the drugs raw materials will be shared through the mechanism.
The U.S. Department of Health and Human Services published a new Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. Individual patients, as well as the health of the public, benefit when opioids are prescribed only when the benefit of using opioids outweighs the risks.
Aclaris Therapeutics Inc., a Chester County biopharmaceutical company that last month unveiled a new strategy to focus, has sold a medicine used to treat rosacea in a deal valued at up to $55 million.
Research & Study
Podcast
FDA Commissioner Discusses Hopes For LDT Legislation by Pharma Intelligence | Free Listening on SoundCloud
Job Opportunities
Upcoming Events
Video
What really happens when you mix medications? | Russ Altman
What really happens when you mix medications? | Russ Altman
Did you enjoy this issue?
Abdul Menum Ali

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue